Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)
CompletedPhase 1, PHASE2Results postedLast updated 10 January 2022
What this trial tests
Phase 1, PHASE2 trial testing tirofiban hydrochloride (AGGRASTAT®) in Subarachnoid Hemorrhage, Aneurysmal in 30 participants. Completed in 1 July 2021.
Adults 18 to 85, any sex, with Subarachnoid Hemorrhage, Aneurysmal. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic)Primary· Day 1 to Day 7
The hypothesis is that the prevalence of intracranial hemorrhage (symptomatic and asymptomatic) secondary to ventriculostomy/VPS placement during the course of Aggrastat use is within 10% difference when compared to control using Day 1 and Day 7 non-contrast head CT to determine.
Group
Value
95% CI
Tirofiban Hydrochloride (AGGRASTAT®)
2
Standard of Care Control Arm
1
Number of Participants With Delayed Cerebral Ischemia /Clinical VasospasmPrimary· Day 1 to Day 7
The measurement of then incidence of delayed cerebral ischemia /clinical vasospasm in Tirofiban/Aggrastat group vs. placebo
Group
Value
95% CI
Tirofiban Hydrochloride (AGGRASTAT®)
1
Standard of Care Control Arm
4
Adverse events — posted to ClinicalTrials.gov
Time frame: Enrollment to 1 year follow up appointment (+/- 1 month from enrollment).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Tirofiban Hydrochloride (AGGRASTAT®)
Serious: 18/18 (100%)
Deaths: 1/18
Standard of Care Control Arm
Serious: 12/12 (100%)
Deaths: 0/12
Serious adverse events (23 terms)
Reaction
System
Tirofiban Hydrochloride (A…
Standard of Care Control Arm
Clinical Vasospasm
Nervous system disorders
—
—
Hypotension
Cardiac disorders
—
—
Acute Hypoxic Respiratory Failure
Respiratory, thoracic and mediastinal disorders
—
—
Deep Vein Thrombosis (DVT)
Vascular disorders
—
—
Pneumonia
Infections and infestations
—
—
Atrial fibrillation with rapid ventricular response
This is a phase 1/2a, randomized, double blind, single-center study comparing standard care alone to standard care with Aggrastat in patients diagnosed with aneurysmal subarachnoid hemorrhage.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Subarachnoid Hemorrhage, Aneurysmal
Currently open trials in the same condition.
NCT04696523 — Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
· Phase 2
· recruiting
NCT06819657 — Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid H
· NA
· recruiting
NCT06766422 — AI Models for Cerebral Aneurysms Segmentation, Detection and Stability Prediction
· recruiting
NCT06906432 — Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage
· recruiting
NCT06218654 — Hemodynamic Instability of Patient With Spontaneous Subarachnoid Hemorrhage
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by David Hasan
Last refreshed: 10 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03691727.